Eli Lilly Message Board - Msg: 33166562

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly

LLY 820.30

-0.7%

Oct 28 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Moonray	1/27/2021 10:24:55 AM
	of 636

Eli Lilly teams up with pharma rival GSK and partner Vir for COVID-19 antibody cocktail test COVID-19 has been a real leveler in competitor terms; once warring Big Pharmas have joined forces for the greater good on vaccines, both in R&D and more recently on production, and now on treatments. Today, Lilly penned a deal with GlaxoSmithKline and biotech partner Vir to wed the former’s emergency-cleared COVID-19 antibody bamlanivimab 700 mg with GSK/Vir’s experimental therapy VIR-7831 (aka GSK4182136) 500 mg. The hope is that in the so-called Blaze-4 trial, which has been expanded to accommodate this combo, will see the two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein create better potency and make the virus less likely to evade, especially with new variants. More at: Eli Lilly teams up with pharma rival GSK and partner Vir for COVID-19 antibody cocktail test o~~~ O

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next